

# The Draupadi of dyslipidemia: Familial hypercholesterolemia

Sanjay Kalra, JPS Sawhney<sup>1</sup>, Rakesh Sahay<sup>2</sup>

Department of Endocrinology, Bharti Hospital, Karnal, Haryana, <sup>1</sup>Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, <sup>2</sup>Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India

Modern medicine is often criticized for disease mongering and noun piling. Menopause and andropause, for example, are criticized by skeptics, who highlight the lack of need for such diagnostic labels.<sup>[1]</sup> Paradoxically, however, modern endocrinology may overlook relatively less common disorders which fall within its ambit. Type 1 diabetes, for instance, is a condition which has to fight for its place under the sun, distinct from the shadow of its ubiquitous cousin, Type 2 diabetes.<sup>[2]</sup>

A similar situation holds true in lipid metabolism. Familial hypercholesterolemia (FH),<sup>[3]</sup> a well-known genetic disease with well-characterized lipo-phenotypes, is often buried under the Himalayan burden of mixed dyslipidemia. This is especially true in Asian nations, where limited diagnostic and therapeutic facilities, coupled with the lack of awareness, lead to under-recognition, misdiagnosis, inadequate treatment, and suboptimal outcomes in FH. This forms the noesis of our editorial.

FH is a distinct genetic condition, found to be more common than thought earlier.<sup>[4]</sup> Recent data suggest that it may occur in up to 0.73% of the Danish population.<sup>[5]</sup> In Australia, 1 out of 267 adolescents is reported to have FH.<sup>[6]</sup> This makes FH much more common than other genetic disease such as Down's syndrome or Turner's syndrome.

Commonly, an autosomal co-dominant disease caused by mutation in the low-density lipoprotein (LDL) receptor gene, it may also be caused by mutation in proprotein convertase subtilisin/kexin Type 9 (PCSK9), apolipoprotein B (Apo B), or hypercholesterolemia adaptor protein (HAP) genes. Both homozygous (HoFH) and heterozygous (heFH) variants are known. HAP is characterized by extremely high LDL cholesterol, cutaneous and tendinous xanthomas,

valvular and supra-valvular stenosis, and premature onset of atherosclerosis and cardiovascular disease (CVD).

Various clinical criteria have been developed to aid in the diagnosis of FH and are accepted as an inexpensive, low technology, yet feasible, sensitive means of screening. Multiple international guidelines describe procedures for the screening, diagnosis, and management of FH.<sup>[7-13]</sup> In spite of this, however, <1% of the population with FH is estimated to have been diagnosed properly, even in developed nations.<sup>[14,15]</sup>

Late (or no) diagnosis and inadequate treatment lead to uncontrolled lipid levels, and do not help arrest the natural history of FH, which culminates in premature atherosclerosis and CVD. This, in no small way, contributes to be pandemic of metabolic disease and CVD that we all are uncomfortably familiar with.

Among the list of characteristics that a disease should have, in order to qualify for screening, the availability of intervention to prevent or treat it.<sup>[16]</sup> One of the reasons for the lack of interest in FH may be the lack of potent medical lipid-lowering therapy (LLT). Till recently, only high-intensity statins and apheresis were available for the management of FH. As results of medical LLT have hardly been encouraging, this may have acted as a deterrent to proactive screening.

In the past few years, three new classes of drugs have been approved by the US Food and Drug Administration for the management of HoFH. These include microsomal triglyceride transfer protein inhibitors (lomitapide), Apo B synthesis inhibitors (mipomersen), and PCSK9 inhibitors (PCSK9i) (alirocumab, evolocumab).<sup>[17]</sup> Results from Phase 2 and Phase 3 trials for PCSK9i, in particular, hold hope for better results in FH care.<sup>[18]</sup> Evolocumab is reported to be effective in lowering levels of LDL cholesterol in patients with both heterozygous and homozygous FH, with or without concomitant administration of cholesterol-lowering treatment. The maximum reductions in plasma levels of LDL cholesterol observed in patients

**Corresponding Author:** Dr. Sanjay Kalra,  
Department of Endocrinology, Bharti Hospital,  
Karnal, Haryana, India.  
E-mail: brideknl@gmail.com

with heterozygous disease were 59.2% (for patients treated with 140 mg evolocumab every 2 weeks) and 61.0% (for patients treated with 420 mg evolocumab monthly). Thus, PCSK9i are heralds of hope for specific target-oriented treatment of FH.

All these developments, however, have not translated into tangible benefits for the Indian FH community at large. Indian guidelines on lipid management pay fleeting attention to FH.<sup>[19]</sup> No independent risk scores or screening tools have been created for the Asian lipo-phenotype. Published data on FH from India is scarce and is limited to small case series and sporadic case reports.<sup>[20-22]</sup> No nationwide screening program or registry is operational, through these activities are essential if we wish to halt the endemic of premature CVD, in the country.

One explanation may be the lack of “ownership” of FH. While multiple subspecialties profess to manage dyslipidemia, few (at least in India) has advocated for the cause of FH. Internal medicine, pediatrics, cardiology, endocrinology, and neurology, all list dyslipidemia as a risk factor to be screened for, prevented, and treated. The sheer magnitude of mixed dyslipidemia that they deal with, however, perhaps prevents them from recognizing and espousing the special needs of people with FH.

The situation of FH is similar to that of Princess Draupadi, the heroine of the Mahabharata. Married to five powerful brothers, the Pandavas, she should have led a life of luxury. Yet, when she needed help, none came to her rescue. Similarly, FH seems to be neglected, even though the lobby for lipid control and CVD prevention is strong. FH needs the support of all concerned specialties, who must work together to sensitize physicians in this regard. Simple screening tools should be developed and popularized, and capacity building carried out for genetic confirmation. The approval of modern LLT, such as PCSK9i, should be fast tracked, to help reduce the burden of uncontrolled LH, accelerated atherosclerosis, and premature CVD in the country.

In the Mahabharata, it took nearly 14 years for Draupadi to get justice. We all need to act, together, to ensure that FH, the Draupadi of dyslipidemia, does not have to wait that long.

## REFERENCES

- Perls T, Handelsman DJ. Disease mongering of age-associated declines in testosterone and growth hormone levels. *J Am Geriatr Soc* 2015;63:809-11.
- Kumar KM, Azad K, Zabeen B, Kalra S. Type 1 diabetes in children: Fighting for a place under the sun. *Indian J Endocrinol Metab* 2012;16 Suppl 1:S1-3.
- Brinton E, Moriarty P, McGowan M, Underberg J. Familial hypercholesterolemia. *Med Roundtable Cardiovasc Ed* 2014;4:e8-e17.
- Ferrières J, Combis MS, Verdier C, Genoux AL, Gennero I, Hamdi S, *et al.* 0084: Big data and LDL: Heterozygous familial hypercholesterolemia is common in France. *Arch Cardiovasc Dis Suppl* 2016;8:95.
- Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: Screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. *Eur Heart J* 2016. pii: Ehw028. [Epub ahead of print].
- Pang J, Martin AC, Mori TA, Beilin LJ, Watts GF. Prevalence of Familial Hypercholesterolemia in Adolescents: Potential Value of Universal Screening? *J Pediatr* 2016;170:315-6.
- Civeira F. International panel on management of familial hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis* 2004;173:55-68.
- Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, *et al.* Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol* 2011;5 3 Suppl: S1-8.
- Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, *et al.* Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J* 2014;35:2146-57.
- Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, *et al.* Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *Int J Cardiol* 2014;171:309-25.
- Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ* 1991;303:893-6.
- World Health Organization. Familial Hypercholesterolemia-Report of a Second WHO Consultation. Geneva, Switzerland: World Health Organization; 1999. [WHO Publication No. WHO/HGN/FH/CONS/99.2].
- Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, *et al.* Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol* 1993;72:171-6.
- Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, *et al.* Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. *Eur Heart J* 2013;34:3478-90.
- Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: Prospective registry study. *BMJ* 2000;321:148.
- Wilson JM, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization; 1968. [Public Health Paper No. 34].
- Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. *Atherosclerosis* 2012;223:262-8.
- Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A, *et al.* PCSK9 inhibitors and their role in high-risk patients

in reducing LDL cholesterol levels: Evolocumab. *Future Cardiol* 2016;12:139-48.

19. Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians: Part 1; 2016. Available from: [http://www.japi.org/march\\_2016\\_special\\_issue/01\\_lipid\\_association\\_of.pdf](http://www.japi.org/march_2016_special_issue/01_lipid_association_of.pdf). [Last accessed on 2016 Mar 19].
20. ArulJothi KN, Whitthall RA, Futema M, Humphries SE, George M, Elangovan S, *et al.* Molecular analysis of the LDLR gene in coronary artery disease patients from the Indian population. *Clin Biochem* 2016. pii: S0009-912000075-8.
21. Setia N, Sawhney JP, Saxena R, Verma IC. Successful role of cascade screening in familial hypercholesterolemia in Indian population. *Cardiology* 2015;131:251.
22. Ghosh SK, Majumder B, Dutta A. Tuberos xanthoma as a presenting feature of familial homozygous hypercholesterolemia with aortic regurgitation. *J Pediatr* 2015;166:198.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online	
<b>Quick Response Code:</b>	<b>Website:</b> www.ijem.in
	<b>DOI:</b> 10.4103/2230-8210.179985

**Cite this article as:** Kalra S, Sawhney J, Sahay R. The Draupadi of dyslipidemia: Familial hypercholesterolemia. *Indian J Endocr Metab* 2016;20:285-7.